• Users Online: 519
  • Print this page
  • Email this page
CASE REPORT
Year : 2022  |  Volume : 2  |  Issue : 3  |  Page : 722-724

Tamoxifen maculopathy mimicking type-2 macular telangiectasia (MacTel-2)


Department of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, India

Correspondence Address:
Dr. Anantharaman Giridhar
Department of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_459_22

Rights and Permissions

Tamoxifen citrate is an antiestrogen agent used in the treatment of breast carcinoma. Incidence of ocular toxicity, in the range of 0.9–-11%, has been reported following its use. Since the clinical picture, especially crystals and cavitation, seen in tamoxifen maculopathy resembles type-2 macular telangiectasia (MacTel-2), differentiating them requires detailed multimodal imaging. We present a rare case of tamoxifen maculopathy mimicking MacTel-2 in an Indian patient. A 55-year-old female with a history of breast carcinoma had been taking tamoxifen 20 mg once daily (cumulative dose of 57.6 g) for 8 years. Color fundus photo showed crystals in foveal and parafoveal region. Further multimodal imaging with confocal blue reflectance, spectral domain optical coherence tomography, fundus autofluorescence, and OCT-angiography demonstrated close resemblance to MacTel-2 features. Thus, it is important to elicit a detailed history in female patients with a history of breast carcinoma and seek oncology consultation once tamoxifen toxicity is seen.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed165    
    Printed2    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal